CureVac N.V. (5CV.F)
EUR 3.15
(-2.48%)
EUR 3.15
(-2.48%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -360.92 Million EUR | 20.45% |
| 2022 | -453.71 Million EUR | 42.02% |
| 2021 | -782.57 Million EUR | 39.45% |
| 2020 | -1.29 Billion EUR | -2766.94% |
| 2019 | 48.46 Million EUR | 327.5% |
| 2018 | -21.3 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -163.57 Million EUR | 37.0% |
| 2024 Q1 | -259.51 Million EUR | 28.1% |
| 2023 Q2 | -497.44 Million EUR | 13.69% |
| 2023 FY | -360.92 Million EUR | 20.45% |
| 2023 Q1 | -576.37 Million USD | -27.04% |
| 2023 Q3 | -422.03 Million EUR | 15.16% |
| 2023 Q4 | -360.92 Million EUR | 14.48% |
| 2022 Q3 | -499.6 Million EUR | 6.33% |
| 2022 Q2 | -533.35 Million EUR | 13.63% |
| 2022 Q1 | -617.54 Million EUR | 21.09% |
| 2022 FY | -453.71 Million EUR | 42.02% |
| 2022 Q4 | -453.71 Million EUR | 9.19% |
| 2021 Q4 | -782.57 Million EUR | 22.09% |
| 2021 Q3 | -1 Billion EUR | 24.3% |
| 2021 Q1 | 1.32 Billion EUR | 202.33% |
| 2021 FY | -782.57 Million EUR | 39.45% |
| 2021 Q2 | -1.32 Billion EUR | -200.32% |
| 2020 Q1 | 56.01 Million EUR | 15.57% |
| 2020 Q4 | -1.29 Billion EUR | -49.99% |
| 2020 Q3 | -861.75 Million EUR | -2019.62% |
| 2020 Q2 | 44.89 Million EUR | -19.85% |
| 2020 FY | -1.29 Billion EUR | -2766.94% |
| 2019 Q1 | 60.63 Million EUR | 0.0% |
| 2019 FY | 48.46 Million EUR | 327.5% |
| 2019 Q4 | 48.46 Million EUR | 0.0% |
| 2018 FY | -21.3 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| BioNTech SE | -11.44 Billion EUR | 96.846% |
| Biotest Aktiengesellschaft | 571.3 Million EUR | 163.176% |
| Biotest Aktiengesellschaft | 571.3 Million EUR | 163.176% |
| BRAIN Biotech AG | -693 Thousand EUR | -51981.577% |
| Formycon AG | 2.45 Million EUR | 14825.636% |
| Heidelberg Pharma AG | -37.6 Million EUR | -859.715% |
| Medigene AG | -5.72 Million EUR | -6205.474% |